SYN-004

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
012320142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
AIM To evaluate an antibiotic inactivation strategy to protect the gut microbiome from antibiotic-mediated damage. METHODS AND… (More)
Is this relevant?
2017
2017
SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
2016
2016
The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex… (More)
Is this relevant?
2016
2016
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be… (More)
Is this relevant?
2016
2016
BACKGROUND SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous… (More)
Is this relevant?
2014
2014
Background. ß-lactam antibiotics that are excreted into the intestine can damage the microflora, which can lead to serious… (More)
Is this relevant?